The 1 analysts offering 12-month price forecasts for InVivo Therapeutics Holdings Corp have a median target of 37.50, with a high estimate of 37.50 and a low estimate of 37.50. The median estimate represents a +7,171.67% increase from the last price of 0.52.
The current consensus among 1 polled investment analysts is to Buy stock in InVivo Therapeutics Holdings Corp. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$9.00
Reporting Date Feb 28
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.